1000/1000
Hot
Most Recent
The fibrosis-4 (FIB-4) index is the first triaging tool for excluding advanced fibrosis because of its accuracy, simplicity, and cheapness, especially for general physicians or endocrinologists, although the FIB-4 index has several drawbacks. Accumulating evidence has suggested that vibration-controlled transient elastography (VCTE) and the enhanced liver fibrosis (ELF) test may become useful as the second step after triaging by the FIB-4 index. The leading cause of mortality in MAFLD is cardiovascular disease (CVD), extrahepatic malignancy, and liver-related diseases. MAFLD often complicates chronic kidney disease (CKD), resulting in increased simultaneous liver kidney transplantation. The FIB-4 index could be a predictor of not only liver-related mortality and incident hepatocellular carcinoma, but also prevalent and incident CKD, CVD, and extrahepatic malignancy.
Index | Formula | Strengths | Weaknesses |
---|---|---|---|
FIB-4 index [15][16] |
(age [years] × AST [U/L]/(platelet count [109/L] × √ALT [U/L]) https://www.eapharma.co.jp/medicalexpert/product/livact/fib-4/calculator.html (accessed on 25 January 2021) |
|
|
NAFLD fibrosis score [26] |
−1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × impaired fasting glucose/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio–0.013 × platelet count (×109/L) − 0.66 × albumin (g/dL) http://nafldscore.com/ (accessed on 25 January 2021) |
|
|
APRI [27] |
AST to platelet ratio index |
|
|
BARD [28] |
BMI > 28 kg/m2 = 1 point AST/ALT ratio > 0.8 = 2 points Diabetes = 1 point |
|
|
CA-fibrosis index [29] |
1.5 × type IV collagen 7S (ng/mL) + 0.0264 × AST (IU/l) |
|
|
ELF test [22] |
−7.412 + (In [HA] × 0.681) + (In [P3NP] × 0.775) + (In [TIMP1] × 0.494) |
|
|
Cutoff Values | No. of Studies (No. of Patients) | Summary Sensitivity, %, Mean (Range) | Summary Specificity, %, Mean (Range) | Summary PPV, %, Mean (Range) | Summary NPV, %, Mean (Range) |
---|---|---|---|---|---|
APRI | |||||
0.452–0.50 | 5 (729) | 72.9 (50.0–87.4) |
67.7 (43.1–91.0) |
44.8 (22.9–71.0) |
89.4 (84.9–95.0) |
0.54–0.98 | 7 (1,351) | 68.6 (61.0–76.2) |
72.7 (59.4–86.0) |
61.4 (46.9–76.2) |
77.6 (59.4–94.0) |
1.00 | 4 (1101) | 43.2 (27.0–67.0) |
86.1 (81.0–89.0) |
33.5 (26.0–40.0) |
89.8 (84.0–95.0) |
1.50 | 4 (682) | 32.9 (6.3–70.0) |
90.5 (74.5–97.0) |
55.5 (40.0–72.1) |
79.1 (73.2–87.2) |
FIB-4 index | |||||
1.24–1.45 | 10 (2759) | 77.8 (63.0–90.0) |
71.2 (55.5–88.0) |
40.3 (24.0–50.6) |
92.7 (88.0–98.0) |
1.51–2.24 | 8 (1533) | 77.0 (70.6–89.5) |
79.2 (67.1–93.6) |
66.4 (37.4–85.7) |
83.9 (58.6–97.2) |
2.67 | 6 (1910) | 31.9 (12.0–63.2) |
95.7 (88.3–98.7) |
66.0 (51.1–80.0) |
85.0 (79.4–92.6) |
3.25 | 6 (1890) | 37.3 (5.0–56.0) |
95.8 (89.0–100) |
72.5 (37.0–100) |
87.3 (78.5–94.0) |
5.31–10.62 | 4 (543) | 67.5 (50.0–100) |
80.8 (54.0–100) |
90.0 (80.0–100) |
85.1 (80.0–90.2) |
BARD | |||||
1.5 | 1 (242) | 83.0 | 59.0 | 34.0 | 93.0 |
2 | 14 (3057) | 75.2 (41.7–100) |
61.6 (32.5–88.9) |
38.3 (15.0–79.8) |
88.7 (49.6–100) |
3–4 | 5 (736) | 59.4 (33.3–85.2) |
75.1 (59.9–91.8) |
55.2 (24.0–69.2) |
81.0 (71.4–90.1) |
NFS | |||||
(−26.93)–(−2.16) | 2 (106) | 80.5 (78.0–83.0) |
69.5 (69.0–70.0) |
None | None |
−1.455 | 10 (3057) | 72.9 (22.7–96.0) |
73.8 (42.9–100) |
50.4 (24.0–100) |
91.8 (81.3–98.1) |
(−1.31)–(0.156) | 5 (963) | 78.2 (69.0–86.4) |
71.7 (60.0–83.0) |
58.4 (34.0–80.8) |
82.1 (54.1–95.0) |
0.67–0.676 | 14 (3896) | 43.1 (8.3–100) |
88.4 (25.0–100) |
66.9 (26.0–100) |
88.5 (78.6–100) |
0.735 | 1 (235) | 68.4 | 88.3 | 53.0 | 93.5 |
Subjects | N | Nation | Dx | Observation Period | Over-all Mortality /Morbidity |
Liver-Related Mortality/Morbidity | Liver Event | HCC | CVD Mortality | Extrahepatic Cancer |
---|---|---|---|---|---|---|---|---|---|---|
NAFLD [62] | 646 | Sweden | Biopsy | 19.9 ±8.7 years |
FIB-4 ○ | FIB-4 ○ | ||||
NFS ○ | NFS ○ | |||||||||
Viral hepatitis-negative adults [61] |
14,841 | USA | General population | Median 19.3 years (IRQ, 17.5–21.1) years | APRI ○ | APRI ○ | FIB-4 ○ | APRI ○ | ||
FIB-4 ○ | FIB-4 ○ | |||||||||
NFS ○ | NFS ○ | |||||||||
Forns score ○ | Forns score○ | |||||||||
NAFLD [57] | 153 | Israel | Biopsy | 100 months (mean) |
FIB-4 ○ | FIB-4 ○ | FIB-4 ○ | |||
NFS ○ | NFS ○ | NFS ○ | ||||||||
APRI × | APRI ○ | APRI ○ | ||||||||
NAFLD [68] | 180 | China | US | 6.6 (range 0.5–14.8) years |
NFS ◎ | |||||
FIB-4 ○ | ||||||||||
APRI× | ||||||||||
BARD× | ||||||||||
NAFLD [58] | 646 | Japan | Biopsy | FIB-4 ○ | FIB-4 ○ | FIB-4 × | ||||
NAFLD [64] | 4073 | Japan | US | NFS ○ | NFS ○ | |||||
NAFLD with diabetes [63] |
284 | Australia | US | 51.4 (range 6.1–146). months |
NFS × | |||||
FIB-4 × | ||||||||||
APRI × | ||||||||||
NAFLD [60] | 11,154 | US | US | 14.5 years | FIB-4 ○ | FIB-4 ○ | ||||
NFS ○ | NFS ○ | |||||||||
APRI ○ | APRI ○ | |||||||||
NASH [69] |
148 | Canada | biopsy | Median: 5 years (IQR: 3–8) | FIB-4 ○ | |||||
NFS ○ | ||||||||||
APRI ○ | ||||||||||
NAFLD [59] |
153 | US | biopsy | Median 104.8 (range, 3–317) months | NFS ◎ | |||||
FIB-4 ○ | ||||||||||
APRI ○ |
Over-Referral | Under-Referral | |
---|---|---|
FIB-4 index low COI | 1.3 | 1.45 |
GP | Work ↓ | Work ↑ |
Hepatologists | Work ↑ | Work ↓ |
Unnecessary liver biopsy | May increase | May reduce |
HCC early detection | Possible? | May delay diagnosis? |
Heath economic costs | High? | Low? |
FAST score =e−1.65+1.07×In(LSM)+2.66×10−8×CAP863.3×AST−11+e−1.65+1.07×In(LSM)+2.66×10−8×CAP3−63.3×AST−1
Author | Subjects | Outcomes | Parameter Correlated with Pathological Improvement |
---|---|---|---|
Hamaguchi [121] |
MAFLD (n = 39) | Hepatic fibrosis | ⊿HbA1c reduction |
Seko [122] |
Steatohepatitis (n = 52) | NAS Hepatic fibrosis |
⊿ALT reduction ≥ 30% from baseline |
Hoofnagle [123] |
Steatohepatitis (n = 139) without DM PIVENS trial |
NAS Hepatic fibrosis |
⊿ALT reduction ≥ 30% from baseline or post-treatment ALT ≤ 40 IU/L |
Vilar-Gomez [124] |
Steatohepatitis (n = 261) | NASH resolution w/o worsening fibrosis | ⊿BW reduction, absence of T2D ALT normalization, younger age, NAS < 5 |
Vuppalanchi | Adult steatohepatitis (n = 231) Pediatric MAFLD (n = 152) |
Histological improvement | ⊿CK18 reduction (inferior to ⊿ALT reduction) |
Siddiqui [119] |
MAFLD (n = 292) | Hepatic fibrosis | ⊿FIB-4 index, ⊿NFS, ⊿APRI |
Jayakumar [111] |
Steatohepatitis, stage 2–3 (n = 54) Selonsertib (Phase 2) |
Hepatic fibrosis | ⊿MRE |
Hepatic steatosis | MRI-PDFF > 25% reduction | ||
Chalasani [120] |
Steatohepatitis (n = 200) FLINT trial (Phase 2) Placebo vs. OCA 72wk |
Hepatic fibrosis | ⊿FIB-4 index ⊿APRI (⊿NFS: no correlation) |
Loomba | NAS ≥ 2 points reduction without worsening fibrosis | OCA(+), pretreatment NAS > 5, TG ≤ 154 mg/dL, INR < 1, AST < 49 IU/L, ⊿ALT at 24wk (>17 IU/L) |